Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma

Dan T. Vogl, MD, MSCE, Edward A. Stadtmauer, MD, James Bradner, MD, Lisa Davis, PharmD, Thomas M. Paul, Emma C. Scott, MD, Charles W. Nichols, MD, David L. Porter, MD, Martin Carroll, MD, Janeen Kaplan, Gayle Mallon, Cezary R. Swider, Patricia A. Mangan, Brenda K. Shelly, Ravi K. Amaravadi, MD

Blood (2011) 118 (21): 1869.

https://doi.org/10.1182/blood.V118.21.1869.1869

Published: 2011

Journal Articles

Effect of Obesity and Renal Insufficiency On Toxicity of High-Dose Melphalan for Multiple Myeloma.

Dan T. Vogl, Thomas M. Paul, Eric Stoopler, German Salazar, Lisa Davis, Shiv Kapoor, Babette Zemel, Mark Yudkoff, Gail Jackson, Lisa Basel-Brown, Kenneth Rockwell, Evgueni Daikhin, Cezary R. Swider, John Washington, Maria Raguza-Lopez, Thomas Tenhave, Edward A. Stadtmauer

Blood (2009) 114 (22): 1177.

https://doi.org/10.1182/blood.V114.22.1177.1177

Published: 2009

Journal Articles

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma

Dan T. Vogl, Edward A. Stadtmauer, James E. Bradner, Lisa Davis, Martin Carroll, Charles W. Nichols, Doris Shank, Mary Carberry, Cezary R. Swider, Patricia A. Mangan, Brenda K. Shelly, Craig B. Thompson, Ravi K. Amaravadi

Blood (2008) 112 (11): 3684.

https://doi.org/10.1182/blood.V112.11.3684.3684

Published: 2008

Journal Articles

Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies

Noelle V Frey, Anna Kalota, Melissa Potuzak, Doris Shank, Cezary R Swider, Alison Loren, Edward Stadtmauer, Alexander Perl, Adam Cuker, Barbara Konkle, Suman Sood, Steven Goldstein, Margaret Kasner, David L Porter, Selina M Luger, Alan M Gewirtz

Blood (2008) 112 (11): 4033.

https://doi.org/10.1182/blood.V112.11.4033.4033

Published: 2008

Journal Articles

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Elizabeth O. Hexner, Cynthia Serdikoff, Mahfuza Jan, Cezary R. Swider, Candy Robinson, Shi Yang, Thelma Angeles, Stephen G. Emerson, Martin Carroll, Bruce Ruggeri, Pawel Dobrzanski

Blood (2008) 111 (12): 5663–5671.

https://doi.org/10.1182/blood-2007-04-083402

Published: 2008

Includes: Supplemental data

Journal Articles

Transcriptional Regulation of the Intra-S-Phase Regulator CDC7 in Human Myeloid Leukemic Cells: A New Downstream Target of the C-Myb Protooncogene.

Lindsay B. Thalheim, BA, Susan E. Shetzline, PhD, Cezary R. Swider, PhD, Alan M. Gewirtz, MD

Blood (2005) 106 (11): 1354.

https://doi.org/10.1182/blood.V106.11.1354.1354

Published: 2005

Journal Articles

Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias

Susan E. Shetzline, Ravikumar Rallapalli, Kelley J. Dowd, Shaomin Zou, Yuji Nakata, Cezary R. Swider, Anna Kalota, John K. Choi, Alan M. Gewirtz

Blood (2004) 104 (6): 1833–1840.

https://doi.org/10.1182/blood-2003-10-3577

Published: 2004

NARROW

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma

Effect of Obesity and Renal Insufficiency On Toxicity of High-Dose Melphalan for Multiple Myeloma.

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma

Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Transcriptional Regulation of the Intra-S-Phase Regulator CDC7 in Human Myeloid Leukemic Cells: A New Downstream Target of the C-Myb Protooncogene.

Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias

Email alerts

ASH Publications

American Society of Hematology

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma

Effect of Obesity and Renal Insufficiency On Toxicity of High-Dose Melphalan for Multiple Myeloma.

Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Preliminary Results of a Phase 1/2 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Relapsed or Refractory Myeloma

Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Transcriptional Regulation of the Intra-S-Phase Regulator CDC7 in Human Myeloid Leukemic Cells: A New Downstream Target of the C-Myb Protooncogene.

Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only